45th week of 2013 patent applcation highlights part 52 |
Patent application number | Title | Published |
20130296380 | Novel Ureas for the Treatment and Prevention of Cancer - A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit. | 2013-11-07 |
20130296381 | ISOXAZOLE DERIVATIVES FOR USE AS FUNGICIDES - The present invention relates to isoxazole compounds of formula (I) having fungicidal activity, to agricultural compositions comprising them, and to the use of said compounds and compositions in agriculture for the control of microbial pests, particularly fungal pests, on plants | 2013-11-07 |
20130296382 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS - Heteroaromatic compounds of Formula I: | 2013-11-07 |
20130296383 | DECAHYDRO-1,4-METHANONAPHTHALEN CARBOXAMIDES - The present invention relates to decahydro-1,4-methanonaphthalen carboxamide derivatives of formula (Ia) or (Ib); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2013-11-07 |
20130296384 | N-SUBSTITUTED(6 HALOALKYLPYRIDIN 3 YL)ALKYL SULFOXIMINES AS A SEED TREATMENT TO CONTROL COLEOPTERAN INSECTS - Methods of using N-substituted(6-haloalkylpyridin-3-yl)alkyl sulfoximines, such as sulfoxaflor, as a seed treatment to control Coleopteran insects, such as flea beetles. | 2013-11-07 |
20130296385 | Fast Dissolving Tablet - The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided. | 2013-11-07 |
20130296386 | SMALL MOLECULE RNASE INHIBITORS AND METHODS OF USE - Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. | 2013-11-07 |
20130296387 | TOPICAL NON-AQUEOUS PHARMACEUTICAL FORMULATIONS - The present application relates to non-aqueous pharmaceutical formulations containing an anti-microbial agent. | 2013-11-07 |
20130296388 | PHENOL-CONTAINING AZOLE COMPOSITIONS FOR THE PROTECTION OF INDUSTRIAL MATERIALS - A process for the protection of industrial materials in which a composition, comprising at least one azole and at least one phenol, is employed so as to treat the industrial material. | 2013-11-07 |
20130296389 | Fungicide Active Substance Combinations - The novel active compound combinations comprising 2-[2-(1-chlorocyclopropyl)3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula | 2013-11-07 |
20130296390 | METHOD AND COMPOSITIONS FOR ENHANCING THE SAFETY OF ORALLY ADMINISTERED MAGNESIUM ALPHA-LIPOATE - The present invention relates to oral nutritional and therapeutic products which are useful for enhancing the safety of administering and reducing the adverse effects caused by magnesium alpha-lipoate to a warm-blooded mammal, comprising administering magnesium alpha-lipoate with D-biotin. | 2013-11-07 |
20130296391 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on a plant disease. The composition comprising a compound represented by Formula (1) and one or more fungicidal compound(s) selected from Group (A) shows an excellent controlling activity on a plant disease. Group (A): a group consisting of benomyl and carbendazim | 2013-11-07 |
20130296392 | METHODS FOR THE TREATMENT OF OVERACTIVE BLADDER - Disclosed herein are methods of treating overactive bladder in a patient, the method comprising identifying a patient in need thereof; and administering to the patient a composition comprising tolterodine, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, wherein after the administration C | 2013-11-07 |
20130296393 | METHOD FOR CONTROLLING CLUBROOT - In order to control the clubroot of brassica vegetables which is settled-planted in a farm field, it is necessary to previously treat the seedling with a chemical before settled planting or treat the soil with a chemical, but the clubroot is sometimes not controlled depending on the weather or soil conditions. In addition, the treatment with a fungicidal compound at a high concentration causes a problem of phytotoxicity or crop persistence. An object of the present invention is to solve these problems and provide a method for easily and simply controlling clubroot without causing a problem of phytotoxicity or crop persistence. The present invention provides a method for controlling clubroot, comprising applying cyazofamid to brassica vegetables after seeding or settled planting in a farm field. | 2013-11-07 |
20130296394 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS - The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl) ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2013-11-07 |
20130296395 | Use of Tetramic Acid Derivates for Controlling Animal Pests after Treatment of the Trunk, the Branches, the Influorescences or the Buds - The present invention relates to the use of tetramic acid derivatives of the formulae (I) or (II) | 2013-11-07 |
20130296396 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME - The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition. | 2013-11-07 |
20130296397 | EARLY MARKER OF PROTEINURIA IN PATIENTS TREATED WITH AN ANTI-VEGF TREATMENT - This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided. | 2013-11-07 |
20130296398 | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY - The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate. | 2013-11-07 |
20130296399 | microRNA Biomarkers for Human Breast and Lung Cancer - The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer. | 2013-11-07 |
20130296400 | ANTIDOTES TO ANTISENSE COMPOUNDS - The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound. | 2013-11-07 |
20130296401 | HBV TREATMENT - RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes. | 2013-11-07 |
20130296402 | BASE MODIFIED OLIGONUCLEOTIDES - The present invention relates to oligonucleotides with base modified nucleosides for enhancement of binding affinity. | 2013-11-07 |
20130296403 | TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS - The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity. | 2013-11-07 |
20130296404 | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same - An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells. | 2013-11-07 |
20130296405 | Compounds Having Anti-Adhesive Effects on Cancer Cells - Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3′->P5′ thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells. | 2013-11-07 |
20130296406 | Optically-Based Stimulation of Target Cells and Modifications Thereto - Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in vivo or in vitro environments). | 2013-11-07 |
20130296407 | Combination Therapy for Cancer - An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished. | 2013-11-07 |
20130296408 | MEDULLOBLASTOMA GENES AS TARGETS FOR DIAGNOSIS AND THERAPEUTICS - Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations, markedly fewer than in common adult cancers. In addition to alterations in the Hedgehog and Wnt pathways, our analysis led to the discovery of genes not previously known to be altered in MBs. Most notably, inactivating mutations of the histone H3K4 trimethylase genes MLL2 or MLL3 were identified in 16% of MB patients. These results demonstrate key differences between the genetic landscapes of adult and childhood cancers, highlight dysregulation of developmental pathways as an important mechanism underlying MBs, and identify a role for a specific type of histone methylation in human tumorigenesis. | 2013-11-07 |
20130296409 | COMPOSITIONS AND METHODS FOR GENERATING ADENO-ASSOCIATED VIRAL VECTORS WITH UNDETECTABLE CAPSID GENE CONTAMINATION - In one aspect, the present invention provides an intron-modified cap expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector. | 2013-11-07 |
20130296410 | OLIGONUCLEOTIDE CHELATE COMPLEXES - The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration. | 2013-11-07 |
20130296411 | Use of Artemisinin for Treating Tumors Induced by oncogenic Viruses and for Treating Viral Infections - In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds. | 2013-11-07 |
20130296412 | Artemisinin-Like Derivatives with Cytotoxic and Anti-Angiogenic Properties - The present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds. The present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration. Especially, the present invention relates to dihydroartemisinin compounds (DHA) substituted by, through an ester linkage by a linear or branched C | 2013-11-07 |
20130296413 | N-DESMETHYL-DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - Desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders. | 2013-11-07 |
20130296414 | 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence - Metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for producing a medicament used for treating depression, and related methods of treating depression, pain and urinary incontinence. | 2013-11-07 |
20130296415 | Manufacturing and Packaging Room Temperature Stable Dronabinol Capsules - The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an inert gas atmosphere during blister packaging. The invention also provides a room temperature stable cannabinoid dosage prepared by the methods of the invention. | 2013-11-07 |
20130296416 | SELECTIVE INHIBITION OF BETA1- ADRENERGIC RECEPTORS FOR THE TREATMENT OF PEDIATRIC HEART FAILURE - Provided are methods of treating heart failure in children using B1-selective adrenergic receptor antagonists, alone or in combination with other agents, including B-2-selective adrenergic receptor agonists. | 2013-11-07 |
20130296417 | Theaflavin Compositions, Production, and Method to Control Physiological Disorders in Mammals - A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between about 10% and about 65% TF3. Individual dosage compositions are provided for the control of a physiological disorder comprising about 5% to about 95% theaflavins in a pharmaceutically acceptable vehicle or a dietary supplement vehicle. Further individual dosage compositions are provided which comprise an effective amount of substantially only one theaflavin species selected from the group consisting of TF1, TF2a, TF2b, and TF3. Individual dosage compositions are provided which comprise an effective amount of substantially only two theaflavin species selected from the group consisting of TF1 and TF2a, TF1 and TF2b, TF1 and TF3, TF2a and TF2b, TF2a and TF3, TF2b and TF3. Methods of treatment of human physiological disorders are provided which comprise administering oral dosage forms of the compositions. | 2013-11-07 |
20130296418 | Cosmetic Composition Containing Lingonberry Extract And Its Uses - The invention relates to a cosmetic composition containing lingonberry extract and its use on skin cosmetology thereof. The present invention has provided a lingonberry extract wherein containing polyphenols components including anthocyanidin, procyanidin, resveratrol, catechin and so on. The present invention also relates to the application of lingonberry extract on skin cosmetology, including without limitation whitening, diminishing visible pigmentation, anti-wrinkle, moisturizing, smoothing and improving skin sensitivity. The invention also has revealed drugs, cosmetic compositions and food prepared by using lingonberry extract. Comparing with the prior art cosmetic compositions, the said lingonberry extract of the present invention has higher effects and safe. | 2013-11-07 |
20130296419 | PRODUCTS CONTAINING POLYPHENOL(S) AND L-ARGININE - Foods and pharmaceuticals which contain cocoa and/or nut procyanidin(s) in combination with L-arginine are effective to induce a physiological increase in nitric oxide production in a mammal having ingested the product. A preferred food product is a confection, particularly a dark or milk chocolate containing nuts. The procyanidins may be natural or synthetic and may be provided by food ingredients such as chocolate liquor and/or cocoa solids prepared from underfermented beans and nut skins. The L-arginine may be natural or synthetic and may be provided by food ingredients such as nut meats, nut pastes, and/or nut flours, seeds, seed pastes, and/or seed flours, or gelatin. The beneficial health effects may include, for example, reduced blood pressure, resistance to cardiovascular disease, and anticancer activity. | 2013-11-07 |
20130296420 | NATURAL LYCOPENE CONCENTRATE AND METHOD FOR PRODUCTION THEREOF - Natural lycopene concentrate obtained from a plant structure after alkalinization, solid-liquid separation, acidification and a second solid-liquid separation. The concentrate obtained is highly bioavailable and water-soluble at room temperature. | 2013-11-07 |
20130296421 | ARYLPROPIONYL-ALPHA-PYRONE ANTIBACTERIAL AGENTS - The invention provides a compound of formula (I): or a salt thereof, wherein R | 2013-11-07 |
20130296422 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient - Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) | 2013-11-07 |
20130296423 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 2013-11-07 |
20130296424 | FATTY ACID TREATMENT FOR CARDIAC PATIENTS - A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof. | 2013-11-07 |
20130296425 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS - An object of the present invention is to provide a drug which is effective for prophylaxis or therapy of peripheral nerve disorder occurred as a side effect of the administration of anti-cancer agents. | 2013-11-07 |
20130296426 | ANALGESIC - An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C | 2013-11-07 |
20130296427 | NERAMEXANE FOR THE TREATMENT OR PREVENTION OF TINNITUS RELATED WITH STRESS OR ACUTE HEARING LOSS - Nerarnexane or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tinnitus, wherein said neramexane or a pharmaceutically acceptable salt thereof is administered to a patient afflicted with tinnitus caused by stress or acute hearing loss. | 2013-11-07 |
20130296428 | REDUCTION OF RISK OF OBESITY - A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life. | 2013-11-07 |
20130296429 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 2013-11-07 |
20130296430 | COMPOSITIONS AND METHODS FOR TREATING AUTISM AND AUTISM SPECTRUM DISORDER - The described invention provides a method for treating a behavioral deficit, such as irritability and stereotypic/repetitive behaviors, in a subject with autism spectrum disorder by administering a composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically acceptable salt of N-acetylcysteine. | 2013-11-07 |
20130296431 | GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE - The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use. | 2013-11-07 |
20130296432 | BENZOIC ACID-ENRICHED PLANT EXTRACTS AND USE THEREOF - Disclosed herein are benzoic acid-enriched plant extracts and uses thereof Specifically, benzoic acid-enriched plant extracts free of toxic substances and organic solvents and use thereof are disclosed. More specifically, a benzoic acid-enriched lingonberry extract free of toxic substances and organic solvents and its use as a preservative is provided. | 2013-11-07 |
20130296433 | PHOSPHORUS BINDER COMPOSITION FOR TREATMENT OF HYPERPHOSPHATEMIA - The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy. | 2013-11-07 |
20130296434 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS - Methods, formulations, and compositions for the treatment of amyloidosis are described. | 2013-11-07 |
20130296435 | METHOD OF ENHANCING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 2013-11-07 |
20130296436 | AMIDINE COMPOUNDS AND USE THEREOF FOR PLANT DISEASE CONTROL - An amidine compound represented by formula (1): wherein R | 2013-11-07 |
20130296437 | Treatment of Depression - There is described a method of treatment of a patient suffering from depression, said method comprising the administration of a sub-analgesic amount of tramadol, or a salt thereof. | 2013-11-07 |
20130296438 | METHODS AND COMPOSITIONS FOR USE WITH K-RAS MEDIATED DISORDERS - Methods and compositions that can be used to identify and characterize inhibitors of K-ras localization to the plasma membrane and in doing so inhibit the signal transduction of K-ras. Such compositions can be used to treat K-ras mediated disorders, such as cancer. | 2013-11-07 |
20130296439 | STABILIZED TOLTERODINE TARTRATE FORMULATIONS - A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads. | 2013-11-07 |
20130296440 | PTEROSTILBENE AND CURCUMIN COMBINATION FOR TREATMENT OF OXIDATIVE STRESS AND INFLAMMATION - A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier. The combination containing pterostilbene and curcumin is effective for treatment or prevention of oxidative stress, treatment of digestive disorders including inflammatory bowel disease, and/or to reduce or inhibit inflammation, in both animals and in humans. | 2013-11-07 |
20130296441 | Anti-Obesity Properties of Pterostilbene - We have determined that pterostilbene demonstrates anti-obesity properties. Rats were fed a commercial obesogenic diet supplemented or not with pterostilbene: PT15 (low dose: 15 mg/kg body weight/d) or PT30 (high dose: 30 mg/kg body weight/d) for 6 weeks. Pterostilbene significantly reduced total adipose tissue mass (15.1% in the PT15 group; 22.9% in the PT30 group) without changes in food intake. The activities of lipogenic enzymes were reduced in white adipose tissue and liver. Activities of enzymes involved in liver fatty acid oxidation were significantly increased in the PT30 group. Low dose pterostilbene can reduce body fat by reducing lipogenesis in adipose tissue. At the high dose, two mechanisms contribute to reduction in body fat: (1) decrease in adipose tissue and liver lipogenesis, and (2) an increase in liver fatty acid oxidation. | 2013-11-07 |
20130296442 | LUTEIN/ZEAXANTHIN FOR GLARE PROTECTION - The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin. | 2013-11-07 |
20130296443 | SYSTEM AND METHOD OF TRANS-VENOUS PRE-AORTIC GANGLION ABLATION - A method of modulating a physiological parameter of a patient is provided. The method includes disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion trans-venously and improving the physiological parameter. The method further includes destroying a pre-aortic ganglion cell trans-venously to prevent regeneration. | 2013-11-07 |
20130296444 | COPOLYMER, COMPOSITION AND METHOD FOR MODIFYING RHEOLOGY - A copolymer for modifying rheology is formed of monomer units consisting essentially of at least one first monomer unit comprising a polyhedral oligomeric silsesquioxane having an ethylenically unsaturated radical; at least one second monomer unit comprising an unsaturated oligo-poly(dimethyl siloxane)(meth)acrylate; and a sufficient amount of at least one unsaturated water-soluble monomer, such that the copolymer is soluble in water. A composition may comprise an electrolyte and the copolymer. The rheology of an environment comprising an electrolyte may be modified by adding the copolymer to the environment. | 2013-11-07 |
20130296445 | Natural Lubricant for Direct Compression and Method for Preparing Natural Tablet Using the Same - The present invention relates to a natural lubricant for direct compression and a method of preparing a synthetic additive-free natural tablet using the same. More particularly, the invention provides a crude fat-containing bean powder, which is used as a natural lubricant, and a method of preparing a natural tablet using the bean powder by a dry granulation process which is carried out using a roller compactor. | 2013-11-07 |
20130296446 | AQUEOUS OPHTHALMIC COMPOSITION - This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained. | 2013-11-07 |
20130296447 | Method of Preventing Neurodevelopmental Damage Due to Prenatal Exposure to Environmental Toxins - A method of assessing the risk in female patients of having neurocognitive developmentally disabled children. The method including measuring the toxin concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant. Quantify the risk of neurocognitive developmentally disabled children born to the subject by comparing the toxin concentrations in the subject to reference concentrations utilizing a weighting algorithm. Advise the patient of the quantified risk of having neurocognitive developmentally disabled children. The concentrations of dialkyl phosphates, endocrine disruptors, and xenoestrogens compounds are evaluated. Additionally, the level of PON1 activity may be included in the risk assessment weighting algorithm. | 2013-11-07 |
20130296448 | PROTECTED FISCHER-TROPSCH CATALYST AND METHOD OF PROVIDING SAME TO A FISCHER-TROPSCH PROCESS - A method of preparing a spray dried catalyst by combining spray dried catalyst particles with wax so the spray dried catalyst particles are coated with wax, yielding wax coated catalyst particles, and shaping the wax coated catalyst to provide shaped wax coated catalyst. A method of activating Fischer-Tropsch catalyst particles containing oxides by contacting the catalyst particles with a reducing gas in an activation vessel to produce an activated catalyst, wherein contacting is performed in the absence of a liquid medium under activation conditions. A system for activating a Fischer-Tropsch catalyst containing an activation reactor configured to introduce an activation gas to a fixed or fluidized bed of the Fischer-Tropsch catalyst in the absence of a liquid medium and at least one separation device configured to separate a gas stream comprising entrained catalyst fines having an average particle size below a desired cutoff size from the activation reactor. | 2013-11-07 |
20130296449 | Polyurethane Gel-Like Polymers, Methods and Use in Flexible Foams - Combinations of open cell flexible foams with polyurethane gel-like polymers, in forms such as layers of different forms and shapes, solid sheets, perforated sheets, and particles, and methods of making the combinations are described using a variety of procedures. Alternatively, the resin to make the polyurethane gel-like polymers may be infused into the polyurethane foams. The open cell flexible foam may partially or wholly comprise polyurethane foam and latex foam. | 2013-11-07 |
20130296450 | METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS HAVING PRIMARY HYDROXYL END GROUPS AND POLYURETHANE POLYMERS PRODUCED THEREFROM - The present invention relates to a process for the preparation of polyether carbonate polyols with primary hydroxyl end groups, comprising the steps of reaction of a starter compound containing active hydrogen atoms with an epoxide and carbon dioxide under double metal cyanide catalysis, reaction of the product obtained with a cyclic carboxylic acid anhydride and reaction of this product obtained with ethylene oxide in the presence of a catalyst which contains at least one nitrogen atom per molecule, excluding non-cyclic tertiary amines with identical substituents. The invention furthermore relates to polyether carbonate polyols obtainable by this process, compositions comprising these polyether carbonate polyols and polyurethane polymers based on these polyether carbonate polyols. | 2013-11-07 |
20130296451 | REACTION PRODUCT FROM THE CO-DEHYDRATION OF A SUGAR ALCOHOL AND A POLYOL - A reaction product of the co-dehydration of a sugar alcohol and a reactant polyol having a number average hydroxyl functionality less than 4.0 is disclosed. In some aspects the sugar alcohol comprises mannitol, sorbitol, xylitol, erythritol, or mixtures thereof. In some preferred aspects the sugar alcohol comprises sorbitol. In some aspects the reactant polyol has an average molecular weight of from 40 to 500 Daltons. In some aspects, the reaction product may be suitable for the manufacture of polyisocyanurate foam. In some aspects the reaction product may be mixed with diluent polyols, such as diols, glycols, ethylene glycol, diethylene glycol, dipropylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol and mixtures thereof. | 2013-11-07 |
20130296452 | Custom Monomers and Polymers for Spectacle Lenses - Monomers and polymers used in making spectacle lenses are disclosed. A thermal curing process is disclosed that includes a latent thermal cationic acid generator and optionally a cationic photoinitiator. | 2013-11-07 |
20130296453 | FUNCTIONALIZED NANOPARTICLES - The present invention discloses functionalized nanoparticles comprising on the surface a covalently bound radical of the formula (I) wherein the nanoparticles are SiO | 2013-11-07 |
20130296454 | ROUTES TO POLYACRYLATES - A polyacrylate is obtained by radical polymerization of at least one acrylate monomer (Ac) in the presence of a polymeric photoinitiator. The polymeric photoinitiator is a co-polymer of at least one photoinitiator monomer (A) with at least one monomer (B), and optional additional monomers (C). Rapid polymerization of the acrylate monomer is provided. A method produces a polyacrylate using the polymeric photoinitiator as described, and a polymeric photoinitiator is used as the photoinitiator of radical polymerization of acrylate monomers. | 2013-11-07 |
20130296455 | NOVEL COMPOUND, DYE AND COLORED PHOTOSENSITIVE COMPOSITION - Disclosed are a dye that is excellent in solubility and heat-resistance, and a novel compound that is suitable for the dye, and specifically provides a yellow dye having a maximum absorption wavelength in the region of 420 to 470 nm. Also disclosed are a colored (alkali-developable) photosensitive composition and an optical filter using the dye, and specifically provides a color filter that does not decrease luminance and thus is preferable for an image display device such as a liquid crystal display panel. Specifically, disclosed are a novel compound represented by the following general formula (1), a dye using the compound, and a colored (alkali-developable) photosensitive composition and a color filter. The content of the above-mentioned general formula (1) is as described in the description. | 2013-11-07 |
20130296456 | HIGHLY ABRASION-RESISTANT IMPRINT MATERIAL CONTAINING URETHANE COMPOUND - There is provided an imprint material forming a film having high abrasion resistance even after a pattern has been transferred thereto, specifically an imprint material forming a film having a small number of pieces of scratch when the film after a pattern has been transferred thereto is subjected to a steel wool abrasion test. An imprint material comprising: a component (A): a compound having at least one ethylene oxide unit and having at least one polymerizable group; a component (B): a polycaprolactone-modified urethane compound having a C | 2013-11-07 |
20130296457 | Method For Modifying Polymers Comprising Hydroxyl Groups - The invention relates to a method for reacting polymers (A) comprising hydroxyl groups and which have repetitive structural units of general formula (I), wherein D represents a direct bond between the polymer backbone and a hydroxyl group, a C | 2013-11-07 |
20130296458 | Continuous Method For Reacting Polymers Carrying Acid Groups, With Amines - The invention relates to a method for reacting synthetic poly(carboxylic acids) (A), containing at least 10 repetitive structural units of formula (I), wherein R | 2013-11-07 |
20130296459 | MEDICAL ADHESIVE COMPOSITION - The present invention provides a medical adhesive composition containing poly-gamma-glutamic acid or its salt; and sugar or sugar alcohol, which is edible, water-soluble, anionic and biodegradable. The invention also provides a thickener composition containing poly-gamma-glutamic acid, which can be used as a moisture-absorbing agent, a moisturizing agent and a raw material for cosmetic products. | 2013-11-07 |
20130296460 | IN SITU BONDS - A biocompatible tissue-bonding adhesive composition having a polyol of functionality N. The polyol being terminated has at least one polyisocyanate in solution with at least (N−1)% of the solution having free polyisocyanate. N may be in the range 1.5-8. The polyol may be a branched polypropylene/polyethylene oxide copolymer. | 2013-11-07 |
20130296461 | AQUEOUS COATINGS AND PAINTS INCORPORATING ONE OR MORE ANTIMICROBIAL BIOSURFACTANTS AND METHODS FOR USING SAME - Disclosed is an aqueous coating composition including at least one latex polymer derived from at least one monomer copolymerized or blended with a rhamnolipid and/or sophorolipid biosurfactant. Also provided is an aqueous architectural coating composition including at least one latex polymer derived from at least one monomer copolymerized or blended with a rhamnolipid and/or sophorolipid biosurfactant, at least one pigment, and water. Also provided is a method of preparing an aqueous architectural coating composition such as a latex paint including the above components. | 2013-11-07 |
20130296462 | Lightweight Wall Repair Compounds - Herein are disclosed wall repair compounds comprising at least one or more polymeric binder latex emulsions, one or more inorganic fillers, and comprising an amount of organic polymeric thickener that is less than about 0.1 percent by weight based on the total weight of the wall repair compound. In certain embodiments, the wall repair compound comprises an inorganic filler system selected such that such that synthetic inorganic fillers comprise essentially 100 percent of the inorganic filler used. In certain embodiments, the wall repair compound comprises one or more glycol ether smoothing agents. | 2013-11-07 |
20130296463 | METHOD FOR MANUFACTURING RUBBER COMPOSITION - The present invention relates to a method for producing a rubber composition containing a rubber component (A) of at least one selected from natural rubbers and synthetic dienic rubbers, a filler containing an inorganic filler (B), a silane coupling agent (C) and at least one vulcanization promoter (D) selected from guanidines, sulfenamides, thiazoles, thiurams, dithiocarbamate salts, thioureas and xanthate salts, wherein the rubber composition is kneaded in at least three stages, in the first stage (X) of kneading, the rubber component (A), all or a part of the inorganic filler (B), and all or a part of the silane coupling agent (C) are kneaded, then in the stage (Y) on and after the second stage of kneading but before the final stage, the vulcanization promoter (D) is added and kneaded, and in the final stage (Z) of kneading, a vulcanizing agent is added and kneaded. | 2013-11-07 |
20130296464 | FLUOROELASTOMER GELS - Fluoroelastomeric gel having the following properties:
| 2013-11-07 |
20130296465 | Thermosetting Compositions Containing Isocyanurate Ring - The invention relates to thermosetting compositions containing isocyanurate ring(s) prepared through chain extension of an epoxy resin (a) with carboxyl-functional oligomers (b), which are the reaction product of polyols (i) containing one or more isocyanurate ring(s) and polycarboxylic acids or their anhydrides (ii). The polyols (i) containing one or more isocyanurate ring(s) can be prepared from the reactions of tris (2-hydroxyalkyl) isocyanurates with a modifier from a caprolactone or alkylene oxide, or glycidyl ester or glycidyl ether and mixtures thereof. The epoxy-functional thermosetting compositions containing an isocyanurate ring(s) can be further reacted with unsaturated acids, preferably (meth)acrylic acid, to obtain a curable polyacrylate. Both epoxy-functional isocyanurate and acrylate-functional isocyanurate thermosetting compositions can be further modified with a polyisocyanate to produce a composition that is useful as a reactive adhesive, binder or in other applications. | 2013-11-07 |
20130296466 | PROCESS FOR PREPARING ALUMINIUM TRIHYDROXIDE - The invention relates to a process for the milling-drying of a raw mixture containing aluminum trihydroxide having an average particle size D | 2013-11-07 |
20130296467 | FLAME-RETARDANT POLYOLEFIN RESIN CONTAINING PIPERAZINE-BASED METAL SALT BLEND - The present invention relates to a flame-retardant polyolefin resin containing a blend which comprises 0.1-80 wt % of piperazine metal salts or polymers thereof, 10-80.0 wt % of nitrogen-containing synergists or phosphorus/nitrogen retardants, and 1-50 wt % of inorganic compounds, wherein the sum of the components of the blend is 100 wt %. | 2013-11-07 |
20130296468 | Flame-retardant polyamide compositions filled with ground glass - The present invention relates to flame-retardant compositions based on a thermoplastic polyamide comprising non-fibrous and unfoamed ground glass with specific particle size distribution, geometry and size, and also to the production and the use of the compositions of the invention for producing products, preferably fibres, foils and mouldings of any type. | 2013-11-07 |
20130296469 | Spray-Dried, Hydrous, Kaolin Clay and Methods of Making Same - A method of producing a spray-dried, hydrous kaolin clay is disclosed that includes mixing a hydrous kaolin clay with water, an ammonium polyacrylate or polyacrylic acid, ammonium hydroxide, and a propanolamine selected from the group consisting of 2-amino-2-methyl-1-propanol, 2-methylamino-2-methyl-1-propanol, 1-amino-2-propanol, or mixtures thereof, to produce a viscosity stable dispersed slurry, and spray drying the slurry to produce the spray-dried, hydrous, kaolin clay. A spray-dried, hydrous kaolin clay is also disclosed. | 2013-11-07 |
20130296470 | COATING COMPOSITIONS CONTAINING TETRAMETHYL CYCLOBUTANEDIOL - Disclosed are solvent borne thermosetting coating compositions that contain a curable polyester resin blended with an acrylic copolymer, a crosslinker, and a solvent. The polyester resin contains 2,2,4,4-tetramethyl-1,3-cyclobutanediol and exhibits good dry time, compatibility with acrylic resins, sag resistance and hardness development in a coating composition. The coating compositions can be used to prepare clear coat or pigmented coatings for automotive OEM, auto refinish, and other applications. | 2013-11-07 |
20130296471 | TYRE TREAD - A tyre, which has an improved grip on wet ground, includes a tread formed of at least a rubber composition. The rubber composition includes: 20 to 100 phr of a first diene elastomer bearing at least one SiOR function, with R being hydrogen or a hydrocarbon radical, and with phr referring to parts by weight per hundred parts of elastomer; 100 to 160 phr of a reinforcing inorganic filler; and a plasticizing system. The plasticizing system includes: a content A of between 5 and 60 phr of a hydrocarbon resin having a Tg above 20° C.; and a content B of between 5 and 60 phr of a liquid plasticizing agent. A total content A+B is greater than 45 phr. The rubber composition optionally includes 0 to 80 phr of a second diene elastomer. | 2013-11-07 |
20130296472 | POLYAMIDE COMPOSITION FOR REFLECTOR, REFLECTOR, LIGHT EMITTING DEVICE INCLUDING THE REFLECTOR, AND LIGHTING DEVICE AND IMAGE DISPLAY DEVICE EACH INCLUDING THE LIGHT EMITTING DEVICE - The present invention provides a polyamide composition for a reflector having high heat resistance and good mechanical properties, having excellent adhesion to a sealing material for an LED package, and capable of retaining a high reflectance even after exposure to heat and light intended for the production process of the LED package and the environment in which the reflector is used in the LED package, when it is molded. The present invention is a polyamide composition for a reflector, containing: 30 mass % or more of a polyamide (A) having a melting point of 280° C. or higher; and 25 mass % or more of titanium oxide (B). The total content of the polyamide (A) and the titanium oxide (B) is 75 mass % or more. | 2013-11-07 |
20130296473 | Flame-Retardant Polycarbonate Resin Composition with Scratch Resistance - The present invention relates to an environmentally friendly flame-retardant polycarbonate resin composition having scratch resistance, which includes a specific (meth)acrylic flame-retardant copolymer to improve flame retardancy and scratch resistance. | 2013-11-07 |
20130296474 | FIRE RESISTANT, HIGH FLOW POLY(ARYL ETHER SULFONE) COMPOSITION - Polymer composition (C) containing (i) a poly(aryl ether sulfone) material (M12) composed of a poly(biphenyl ether sulfone) (P1) and, optionally in addition, a poly(aryl ether sulfone) (P2) containing recurring units with arylene groups linked to each other via a secondary, ternary or quaternary carbon atom, and (ii) a per(halo)fluoropolymer material (M34), composed of a per(halo)fluoropolymer (P3) of which at least 2.0 wt. % of the recurring units are derived from a per(halo)fluoromonomer other than tetrafluoroethylene, and a polytetrafluoroethylene (P4). | 2013-11-07 |
20130296475 | RUBBER COMPOSITION INCLUDING A FUNCTIONALIZED THERMOPLASTIC POLYMER - The present invention relates to a diene rubber composition reinforced with an inorganic filler comprising a thermoplastic polymer bearing, at at least one end, a silanol or silyl ether functional group. The presence of the functional thermoplastic polymer makes it possible to improve the compromise of performances, which are the handling and the grip, of a tyre having a tread that is based on such a composition. | 2013-11-07 |
20130296476 | ADHESIVE RESIN COMPOSITION AND HOT MELT ADHESIVE OBTAINED THEREFROM - Object: To provide adhesive resin compositions improved in heat resistance without deteriorations in adhesive strength and flexibility. | 2013-11-07 |
20130296477 | RUBBER COMPOSITION FOR USE IN TIRES, AND PNEUMATIC TIRE - The present invention provides a rubber composition for a tire, which results in both excellent fuel economy and high wet grip performance as well as good abrasion resistance; and a pneumatic tire formed from the rubber composition. The present invention relates to a rubber composition for a tire, the rubber composition containing a modified styrene butadiene rubber formed using a specific nitrogen-containing compound as a monomer, silica, and a specific amount of a diene rubber gel. | 2013-11-07 |
20130296478 | ELASTOMER MATERIAL CONTAINING IMMOBILIZED IONIC COMPONENTS AND METHOD FOR MANUFACTURING THE SAME - An elastomer material containing immobilized ionic components includes an elastomer, ion-immobilized particles in which first ionic components are immobilized to metallic oxide particles, and second ionic components having electric charges opposite to electric charges of the first ionic components, wherein the ion-immobilized particles are chemically bonded to the elastomer. In the elastomer material, the first ionic components are immobilized to the elastomer through the metallic oxide particles. Therefore, the first ionic components do not easily migrate even with the passage of time or in use. Thus, the elastomer material is less susceptible to temporal changes in properties. The elastomer material is preferably used for the component of a transducer and a conductive roll. | 2013-11-07 |
20130296479 | RUBBER FORMULATIONS INCLUDING GRAPHENIC CARBON PARTICLES - Rubber formulations comprising a base rubber composition, graphenic carbon particles, and non-conductive filler particles such as silica are disclosed. The formulations possess favorable properties such as relatively low surface resistivities, and are useful for many applications such as tire treads. | 2013-11-07 |